TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
SYRE

Spyre Therapeutics Inc.

Healthcare · Biotechnology

85.70$ -1.6% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Balance Sheet

Spyre Therapeutics Inc. (SYRE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 1,173 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet SYRE
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
207 342 488 436 421 608 570 539 505 778 764 1,173
206 342 487 436 421 608 570 539 505 778 764 1,173
91 189 228 45 72 89 48 82 65 86 97 162
204 339 485 426 414 603 565 527 486 757 741 1,145
0.2 – – – – – – 3.5 3.6 – 4.6 –
453 158 335 62 94 91 87 83 50 63 93 72
45 32 43 22 58 54 71 83 46 59 85 63
1.7 0.9 3.1 3.2 5.2 0.7 3.7 3.7 7.5 8.9 5.7 5.7
-245 184 152 374 327 518 483 456 455 715 671 1,101
-701 -764 -808 -847 -916 -972 -1,017 -1,054 -1,065 -1,128 -1,197 -1,233
4.3 22 37 45 51 47 60 61 60 75 79 85

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?